Fenbendazole, a commonly used medication for parasitic worm infections and also known as Safe-Guard and Panacur, has been shown to dramatically decrease cancer cell growth in lab tests. This is important because many studies show that the more a cancer cells grow, the harder it is to treat. Fenbendazole, like many other drugs in the benzimidazole family, has been shown to alter numerous molecular pathways that slows cancer growth and ultimately leads to its death.
While Health Canada lists all anthelmintics (parasitic medications) as being for veterinary use only, multiple peer-reviewed scientific publications have demonstrated that animal anthelmintics may also be powerful anti-cancer medicines. Several benzimidazole drugs, including mebendazole and albendazole, are already being repurposed as cancer treatments in humans.
Among these is fenbendazole, which has been shown to exhibit in vivo and in vitro anti-tumor activities when paired with berberine and sodium dichloroacetate (DCA). A recent study found that this drug not only disrupts proteasomal interference and microtubule function, but also impedes glucose absorption by inhibiting GLUT4’s appearance on the surface of cancer cells, thus starving them of their main energy source.
While these findings add to the growing body of evidence that fenbendazole for humans may be an effective cancer treatment, it’s highly advisable that any potential user consults with an integrative healthcare professional first to create a personalized protocol that will minimize side effects and maximize effectiveness. A practitioner can take a detailed medical history and review current test results to determine whether this medication is right for you. fenbendazole for humans